Plain-English translation of NCT04392206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether (AMSC) — special cells taken from fat tissue — can help improve the success of surgery that creates a new blood vessel connection (called a fistula) for dialysis. This treatment would be given during the surgery itself. Researchers want to see if this medication can help the new fistula work better and last longer.
When people with kidney failure need dialysis, they need a reliable way to access their bloodstream for treatment, but the surgical connections often narrow or fail over time. This trial is exploring whether this treatment could reduce those complications and help more patients avoid repeat surgeries.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the stem cell treatment during your planned fistula surgery — the cells would be applied at the surgical site where the blood vessel connection is created. After surgery, the research team would monitor your recovery and the success of the fistula over time through follow-up visits and imaging tests. The study lasts at least 24 months, during which you would have regular check-ins to make sure the treatment is safe and working well.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Houssam Farres, M.D.
Enrollment target
~15 participants
Started
May 2020
Primary completion
December 2026
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Reagan Dukes
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.